Clinical Trial Update: Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 prospective multicenter observational trial evaluating apatinib alone or with capecitabine for metastatic HER2-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Apatinib (apatinib)
• Capecitabine (capecitabine)

Snippet

Sponsor: Hebei Medical University Fourth Hospital | Conditions: Breast Cancer Metastatic | Phase 2 | Status: UNKNOWN